Multi-source·Aug 20, 2026·14 sources analyzed
Moderna and Merck's mRNA cancer vaccine shows promise in trials
Moderna and Merck report results from a late-stage trial of an mRNA vaccine targeting melanoma. The findings indicate the vaccine may assist in preventing cancer recurrence. (sources: cbsnews, ap, axios, nbcnews, abc)
Image: axios
Modern Action Briefing
Moderna and Merck announced that their mRNA cancer vaccine showed effectiveness in preventing melanoma recurrence during a late-stage trial. Following this announcement, shares of both companies saw notable increases.
- The mRNA cancer vaccine passed a key test in a late-stage clinical trial.
- The treatment aims to prevent the recurrence or spread of melanoma.
- Shares of Moderna and Merck rose significantly after the announcement.
Why it matters
The results could represent a significant advancement in cancer treatment using mRNA technology.
Sources used · 14 sources
newscbsnewsHow Moderna's melanoma mRNA vaccine could fight deadliest skin cancernewsapModerna shares surge after it says its experimental mRNA cancer treatment passed a key testnewsaxiosModerna and Merck shares soar on mRNA cancer vaccinenewsnbcnewsMerck and Moderna say cancer vaccine shows signs of preventing recurrence of melanoma